Update in the pharmacotherapy of depression

American Journal of Medicine

Volumn 101, Issue 6 A, 1996, Pages

  Sussman, Norman ^a   Stahl, Stephen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMOXAPINE; CATECHOLAMINE UPTAKE INHIBITOR; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENELZINE; SELEGILINE; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT;

APPETITE DISORDER; CONFERENCE PAPER; DELIRIUM; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; NEUROTRANSMISSION; PRIORITY JOURNAL; SEDATION; SEXUAL DYSFUNCTION; STROKE; WEIGHT GAIN; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS;

EID: 0030607650     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)89538-1     Document Type: Conference Paper

References (17)

1. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant depression. J Clin Psychopharmacol. 1994;14:419-423.
2. Garcia-Monco JC, Padierna A, Gomez BM. Selegiline, fluoxetine, and depression in Parkinson's disease, (letter) Movement Disorders. 1995;10:352.
3. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French selegiline multicenter trial. Movement Disorders. 1993;8(suppl 1):S36-S40.
4. Tsuiki K, Yamamoto L, Diksic M. Effect of acute fluoxetine treatment on the brain serotonin synthesis as measured by the α-methyl-L-tryptophan autoradiographic method. J Neurochem. 1995;65:250-256.
5. Preskorn FH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications, Inc., 1996.
6. Joffe RT, Levitt AJ, Sokolov STH, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115.
7. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry. 1995;56:30-34.
8. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996;57:67-71.
9. Sachette et al. Are SSRI antidepressants a clinically homogenous class of compounds? Lancet. 1994;344:126-127.
10. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry. 1993;54:432-434.
11. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-125.
12. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine. [Letter] Am J Psych. 1991;148:1403.
13. Botsaris SD, Sypek JM. Paroxetine and tardive dyskinesia. [Letter] J Clin Psychopharmacol. 1996;16:258-259.
14. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid downregulation of beta-adrenreceptors by coadministration of fluoxtine and desipramine. Eur J Pharmacol. 1988;154:125-134.
15. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary open study of the combination of fluoxetine and desipramine for the rapid treatment of major depression. Arch Gen Psych. 1991;48:303-307.
16. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia, Int Clin Psychopharmacol. 1994;9:139-143.
17. Preskorn SH. Advances in the pharmacotherapy of depressive disorders. Principles Practice Psychopharmacotherapy. 1995;1:1-24.